RELAY: Final Overall Survival for Erlotinib + Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC

By sjmartinez • December 3, 2024

Nakagawa K, Garon EB, Seto T, Nishio M, Aix SP, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Nishino K, Yoh K, Shih JY, Chik JY, Moro-Sibilot D, Puri T, Varughese SC, Frimodt-Moller B, Visseren-Grul C, Reck M. RELAY: Final Overall Survival for Erlotinib + Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC. J Thorac Oncol. 2024 Nov 30:S1556-0864(24)02495-X. doi: 10.1016/j.jtho.2024.11.032. Epub ahead of print. PMID: 39622410.

Tags: EGFR mutation, erlotinib, Hematology/Oncology, NSCLC, overall survival, Publications, ramucirumab

Somatic Tumor Next-Generation Sequencing in US Veterans With Metastatic Prostate Cancer

Valle LF, Li J, Desai H, Hausler R, Haroldsen C, Chatwal M, Ojo M, Kelley MJ, Rebbeck TR, Rose BS, Rettig MB, Nickols NG, Garraway[...]

Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists

Rugo HS, Bardia A, Gradishar WJ, Hamilton EP, Hurvitz SA, Jhaveri K, Mahtani R, Tolaney SM. Expert consensus on treating HR+/HER2- metastatic breast cancer based[...]

Brief Report: The Genomic Landscape of Small Cell Lung Cancer in Never-Smoking Patients

Oh MS, Garon EB, Lisberg AE, Cummings AL, Barrett A, Ashok A, Mauer E, Yilma B, Goldman JW. Brief Report: The Genomic Landscape of Small[...]